Dr Garzotto reviews efficacy of aglatimagene besadenovec with valacyclovir and radiation in localized prostate cancer
Dr Mark Garzotto presented data on a novel therapeutic approach for localized prostate cancer that combines the gene therapy agent aglatimagene besadenovec with the antiviral drug valacyclovir and external beam radiation therapy (EBRT).
The discussion focused on the observed efficacy of the combination, highlighting how the agents may work together to enhance tumor control, though specific efficacy metrics were not disclosed in the source.
The presentation suggests ongoing interest in integrating gene-based treatments with standard radiation protocols, and further clinical data will be needed to determine the therapeutic value of this regimen.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer”
read at onclive ↗
comments(0)
5-min edit window · permanent after that